TEMPE, Ariz.– Aptyx, a leading global developer and manufacturer of complex components and devices for the life sciences, today announced the acquisition of the Charlotte, North Carolina facility of Medical Murray, which develops and produces catheter-based interventional products and transcatheter implants.
“This marks a significant step in our growth strategy, strengthening our interventional product capabilities and end-to-end offerings, driving innovation, and delivering greater value to our OEM life science customers,” said Gregg Tobin, President and CEO, Aptyx. “It is a key element of our original blueprint and just the beginning of our evolution, with much more growth to follow.”
This acquisition will become an integral part of Aptyx Interventional Systems, fortifying the company’s interventional and implantable expertise with a rich pool of engineering talent.
The transaction enables Design & Development center support and advanced manufacturing for customers and bolsters expertise in catheter-based interventional products and transcatheter solutions, including implantable stents and frames, complex catheters, and delivery systems. It expands the company’s ISO Class 7 footprint and brings particular expertise in biotextiles such as ePTFE covering for stents and frames. Aptyx has long been known for producing highly engineered products and extreme proficiency in the manufacture of mission-critical molding, extrusion, coating solutions and medical device assembly. By combining with Medical Murray, Aptyx will now be able to provide a complete manufacturing solution for catheter-based interventional and implantable products.
Eric Leopold, who served as CTO of Medical Murray and leader of the Charlotte, NC business, will join Aptyx post-acquisition as Senior Vice President. “We’re committed to conquering technical challenges and delivering on time and cost efficient products for the structural heart, vascular, neurovascular, and other key end markets,” noted Leopold. “Joining Aptyx and combining our comprehensive experience in interventional markets provides the rocket fuel for long-term growth.”
Charlotte team members will become part of Aptyx. Medical Murray will continue to operate separately through its two facilities in the Chicagoland area.
“Aptyx Interventional Systems broadens the Aptyx footprint in the high-growth interventional market and adds competitive and high-value manufacturing and Design & Development capabilities,” said John Pless, Co-Managing Partner, TruArc. “Continued investment is planned to further support customers in the life sciences industry, reinforcing Aptyx’s position as a trusted outsource manufacturing partner.”
Parker Poe Adams & Bernstein acted as legal counsel and Raymond James as financial advisor to Aptyx and TruArc Partners. Buckley Fine acted as legal counsel and Areida Group as financial advisor to Medical Murray.
